On November 6, 2024 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting, will be made publicly available on the Company’s website at 12:15pm CT on November 8, 2024 (Press release, Anixa Biosciences, NOV 6, 2024, View Source [SID1234647800]). Concurrently, the Company will issue a press release providing an analysis of the data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously announced, the presentation, titled "Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC," will be presented at 12:15pm CT on November 8, 2024 at the SITC (Free SITC Whitepaper) 39th Annual Meeting.

The poster presentation can be viewed starting at 12:15pm CT on November 8, 2024 at View Source